A critical roadblock in the development of an HIV-1 vaccine is our current inability to deliver HIV-1 antigens efficiently to the immune system and to prime predictable, high frequency immune responses in humans. Recombinant Ad5 vector-based vaccines have elicited potent immune responses in preclinical studies. However, the high frequency of anti-Ad5 immunity in the developing world will likely limit the immunogenicity and clinical utility of rAd5 vaccines. We therefore propose the development of novel, replication-incompetent rAd vector-based vaccines for HIV-1. In this project, we will investigate the hypothesis that novel rAd vector-based vaccines derived from rare Ad serotypes and engineered for improved immunogenicity will elicit potent immune responses in rhesus monkeys with anti-Ad5 immunity. We further hypothesize that heterologous rAd prime-boost regimens utilizing these novel rAd vectors will prove substantially more immunogenic than traditional rAd5 vaccines in the presence of anti-Ad5 immunity. As a key component of these studies, we will systematically compare the immunogenicity and protective efficacy of various rAd vector combinations to determine the optimal vaccine regimen to advance into the clinical studies described in Project 2 of this IPCAVD grant. To investigate these hypotheses, we propose the following five Specific Aims: 1. To compare the immunogenicity of rAd5, rAd35, and capsid chimeric rAd5/rAd35 vectors in rhesus monkeys with anti-Ad5 immunity; 2. To compare the immunogenicity of various heterologous rAd prime-boost regimens in rhesus monkeys with anti-Ad5 immunity and to assess their protective efficacy against a SHIV-89.6P challenge; 3. To assess the immunogenicity and protective efficacy of the optimal heterologous rAd prime-boost regimen against an SIVmac251 challenge in rhesus monkeys with and without anti-Ad5 immunity; 4. To assess the immunogenicity and protective efficacy of limiting vaccine doses of the optimal heterologous rAd prime-boost regimen against a heterologous SIVmac251 challenge in rhesus monkeys with anti-Ad5 immunity;and 5. To determine the protective efficacy of the optimal heterologous rAd prime-boost regimen against repetitive, low-dose, mucosal, heterologous SIVmac251 challenges in rhesus monkeys with anti-Ad5 immunity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI066305-05
Application #
7779405
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
5
Fiscal Year
2009
Total Cost
$1,214,370
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Baden, Lindsey R; Karita, Etienne; Mutua, Gaudensia et al. (2016) Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med 164:313-22
Baden, Lindsey R; Liu, Jinyan; Li, Hualin et al. (2015) Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211:518-28
Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2014) First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 210:1052-61
Barouch, Dan H; Whitney, James B; Moldt, Brian et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:224-8
Barouch, Dan H; Liu, Jinyan; Peter, Lauren et al. (2013) Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 207:248-56
Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2013) First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207:240-7
Stephenson, Kathryn E; SanMiguel, Adam; Simmons, Nathaniel L et al. (2012) Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol 86:11434-40
Li, Hualin; Rhee, Elizabeth G; Masek-Hammerman, Katherine et al. (2012) Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 86:10862-5
Handley, Scott A; Thackray, Larissa B; Zhao, Guoyan et al. (2012) Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 151:253-66
Bradley, Ritu R; Maxfield, Lori F; Lynch, Diana M et al. (2012) Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86:1267-72

Showing the most recent 10 out of 43 publications